Myelodysplastic
(MDS) syndrome is a type of bone marrow disorder, where bone marrow
is unable to produce healthy and mature blood cells. The immature
blood cells called as blasts, get stored in the bone marrow and blood
and obstruct the natural function of the hematological system which
results in depletion of healthy red blood cells, platelets, and white
blood cells. Myelodysplastic syndrome is usually seen in geriatric
population and more often in older men than women. This syndrome is
characterized by certain chromosomal mutations in Janus Kinase gene
which include deletion of q arm in one or more chromosomes and
complete deletion of chromosome 5 or 7 and an extra copy of
chromosome 8. There are various types of myelodysplastic syndrome
such as refractory cytopenia with unilineage dysplasia and refractory
anemia with ringed sideroblasts among others. Approved drugs for MDS
include Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine
(Dacogen), and Deferasirox (Jadenu). Revlimid (Lenalidomide) patent
for MDS indication will be expiring in 2023. A number of generic
azacitidine-based products for MDS are launched in the global market.
Get
In-Depth Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/775
Rising
implications associated with myelodysplastic syndrome are expected to
affect the myelodysplastic syndrome treatment market
According
to the American Cancer Society, the incidence rate for
myelodysplastic syndrome is 13,000 new cases each year which happens
at a rate of 4.8 cases per 100,000 people. This trend is heavily
affected or rather influenced by the average age of the population
which, according to the World Health Organization (WHO), is
increasing and is expected to double from 12% to 22% between 2015 and
2050. Furthermore, according to the American Society of Clinical
Oncology (ASCO), age plays an important role in the occurrence of
myelodysplastic syndrome as most of the people diagnosed with the
disease are of age 65 and older. These factors are expected to boost
the myelodysplastic syndrome treatment.
The
global myelodysplastic syndrome treatment market was valued at US$
2,213.2 million in 2017 and is expected to witness a CAGR of 12.7%
during the forecast period (2017 – 2025).
Endeavor
to introduce highly effective therapies for various MDS types would
support the market growth
Major
pharmaceutical organizations such as Celgene are investing major
amounts in research and development of MDS specific drugs and many of
their drugs are showing potential in the clinical trials as shown in
the table no.1. Furthermore, in 2016, Opsona Therapeutics Ltd.
received orphan drug designation for its OPN-305 humanized IgG4
monoclonal antibody for MDS treatment. Also, after Celgene lost its
U.S. exclusivity for Vidaza, many generic formulations have entered
in the market for Vidaza and Natco Pharma is also expected to launch
generic version of Vidaza in 2017, which will further boost
myelodysplastic syndrome treatment market.
Global
Key Players
Key
players operating in the myelodysplastic syndrome treatment market
include Celgene, Novartis, and Otsuka. Some of the other market
players are Astellas, Astex, Acceleron Pharma, Onconova
Pharmaceuticals, GlaxoSmithKline, Eli-Lilly, and CTI Biopharma.
Detailed
Segmentation:
Global
Myelodysplastic syndrome treatment market, By Drug:
-
Azacitidine
-
Lenalidomide
-
Decitabine
-
Deferasirox
Global
Myelodysplastic syndrome treatment market, By Geography:
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
Browse
In-Depth Analysis Research Report @
https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment